Research Overview

Dr. Garbern is interested in future clinical translation of stem cell-based cardiomyocyte therapies. Current projects focus on cardiomyocyte maturation, strategies to minimize immune system detection of stem cell-derived cardiomyocytes, and cardiac tissue engineering.

Research Background

Dr. Garbern completed her MD/PhD in bioengineering at the University of Washington then completed her clinical training in Pediatrics and Pediatric Cardiology at Boston Children's Hospital.

Education

Undergraduate School

University of Michigan
Ann Arbor MI

Graduate School

University of Washington
Seattle WA

Medical School

University of Washington
Seattle WA

Residency

Boston Combined Residency Program (BCRP)
Boston MA

Residency

Boston Combined Residency Program (BCRP)
Boston MA

Fellowship

Boston Children's Hospital
Boston MA

Publications

  1. P53 Activation Promotes Maturational Characteristics of Pluripotent Stem Cell-Derived Cardiomyocytes in 3-Dimensional Suspension Culture Via FOXO-FOXM1 Regulation. J Am Heart Assoc. 2024 Jul 02; 13(13):e033155. View Abstract
  2. Discovery adductomics provides a comprehensive portrait of tissue-, age- and sex-specific DNA modifications in rodents and humans. Nucleic Acids Res. 2023 11 10; 51(20):10829-10845. View Abstract
  3. Tissue-embedded stretchable nanoelectronics reveal endothelial cell-mediated electrical maturation of human 3D cardiac microtissues. Sci Adv. 2023 03 10; 9(10):eade8513. View Abstract
  4. Senescence mechanisms and targets in the heart. Cardiovasc Res. 2022 03 25; 118(5):1173-1187. View Abstract
  5. Heart regeneration: 20 years of progress and renewed optimism. Dev Cell. 2022 02 28; 57(4):424-439. View Abstract
  6. Mitochondria and metabolic transitions in cardiomyocytes: lessons from development for stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2021 03 12; 12(1):177. View Abstract
  7. Sustained Activation of AMPK Enhances Differentiation of Human iPSC-Derived Cardiomyocytes via Sirtuin Activation. Stem Cell Reports. 2020 08 11; 15(2):498-514. View Abstract
  8. Pluripotent stem cell-derived cardiomyocytes for treatment of cardiomyopathic damage: Current concepts and future directions. Trends Cardiovasc Med. 2021 02; 31(2):85-90. View Abstract
  9. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients. Transplantation. 2020 01; 104(1):e31-e37. View Abstract
  10. Steady-state and regenerative hematopoiesis occurs normally in mice in the absence of GDF11. Blood. 2019 11 14; 134(20):1712-1716. View Abstract
  11. Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence. Circulation. 2020 01 28; 141(4):285-300. View Abstract
  12. Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities. Chem Rev. 2019 11 13; 119(21):11352-11390. View Abstract
  13. Analysis of Cre-mediated genetic deletion of Gdf11 in cardiomyocytes of young mice. Am J Physiol Heart Circ Physiol. 2019 07 01; 317(1):H201-H212. View Abstract
  14. Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis. J Mol Cell Cardiol. 2019 03; 128:179-186. View Abstract
  15. Engineering of mature human induced pluripotent stem cell-derived cardiomyocytes using substrates with multiscale topography. Advanced Functional Materials. 2018; 19(28):1707378. View Abstract
  16. Into the hearts of babes: Stem cell therapy for pediatric heart failure. J Heart Lung Transplant. 2017 08; 36(8):830-832. View Abstract
  17. Is Myocarditis an Independent Risk Factor for Post-Transplant Mortality in Pediatric Heart Transplant Recipients? Circ Heart Fail. 2016 Jan; 9(1):e002328. View Abstract
  18. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell. 2013 Jun 06; 12(6):689-98. View Abstract
  19. Model systems for cardiovascular regenerative biology. Cold Spring Harb Perspect Med. 2013 Apr 01; 3(4):a014019. View Abstract
  20. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials. 2011 Mar; 32(9):2407-16. View Abstract
  21. Injectable pH- and temperature-responsive poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for delivery of angiogenic growth factors. Biomacromolecules. 2010 Jul 12; 11(7):1833-9. View Abstract
  22. Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens. 2005 Jan; 27(1):71-82. View Abstract
  23. Locally enhanced angiogenesis promotes transplanted cell survival. Tissue Eng. 2004 Jan-Feb; 10(1-2):63-71. View Abstract

Contact Jessica Garbern

Print Profile